mTOR inhibitors

Mechanism of Action - The Cell Cycle Brake

• Primary Target: Mammalian Target of Rapamycin (mTOR), a key serine/threonine kinase.
• Action: Sirolimus (Rapamycin) and Everolimus first bind to the intracellular protein FKBP-12.
  • This drug-immunophilin complex then binds to and inhibits mTOR.
• Cellular Effect: Inhibition of mTOR blocks the signal transduction pathway downstream of the IL-2 receptor, arresting the cell cycle at the G1-S phase.
  • This prevents the proliferation of T-lymphocytes.

⭐ Exam Pearl: Unlike calcineurin inhibitors (Tacrolimus, Cyclosporine) which prevent IL-2 synthesis, mTOR inhibitors block the T-cell's response to IL-2 stimulation.

The Drugs & PK - Rapa's Crew

• Sirolimus (Rapamycin)
  • The original macrolide mTOR inhibitor, isolated from the bacterium Streptomyces hygroscopicus.
  • PK: Administered orally; has a long half-life of approx. 60 hours.
• Everolimus
  • A derivative of sirolimus (a "limus" drug).
  • PK: Shorter half-life (~30 hours) and improved oral bioavailability compared to sirolimus.
• Temsirolimus
  • A prodrug that is converted to sirolimus.
  • PK: Administered IV.
• Zotarolimus
  • A sirolimus analog developed for specific applications.
  • PK: Primarily used in drug-eluting stents.

⭐ Sirolimus and its analogs are famously used in drug-eluting stents (DES) to inhibit smooth muscle cell proliferation, thereby preventing coronary artery restenosis following angioplasty.

Clinical Uses - Stents & Transplants

• Drug-Eluting Stents (DES)

  • Sirolimus and everolimus are coated on coronary stents.
  • Action: Block local T-cell proliferation and smooth muscle cell migration.
  • Purpose: Prevents in-stent restenosis after percutaneous coronary intervention (PCI).

• Solid Organ Transplant Rejection

  • Prophylaxis for kidney, liver, & heart transplant rejection.
  • Often used in combination with corticosteroids and calcineurin inhibitors, or as a CNI-sparing agent.

⭐ Kidney-Sparing Effect: mTOR inhibitors are valuable in renal transplant patients with calcineurin inhibitor (e.g., tacrolimus) induced nephrotoxicity, allowing for CNI dose reduction.

Adverse Effects - SIR‑ious Side Effects

📌 Mnemonic: SIR-ious side effects.

• Stomatitis: Painful mouth ulcers and mucositis.

• Insulin resistance: Resulting in hyperglycemia and new-onset diabetes.

• Rash: Acneiform skin eruptions are common.

• Pancytopenia: Dose-related myelosuppression affecting all cell lines (anemia, thrombocytopenia, leukopenia).

• Hyperlipidemia: Significant increases in both cholesterol and triglycerides.

• Impaired wound healing: Due to anti-proliferative effects; caution post-surgery.

• Nephrotoxicity: Potentiates kidney damage from calcineurin inhibitors.

⭐ A key, potentially severe toxicity is non-infectious interstitial pneumonitis. It presents with cough and dyspnea, is dose-dependent, and often reversible upon drug cessation.

High‑Yield Points - ⚡ Biggest Takeaways

• Sirolimus (Rapamycin) and Everolimus inhibit mTOR by binding to FKBP, which blocks IL-2 signal transduction and halts G1-S phase progression.
• Primarily used for prophylaxis of solid organ rejection, especially in kidney transplants, and within drug-eluting stents.
• Major adverse effects include pancytopenia, dose-dependent hyperlipidemia (especially ↑ triglycerides), and insulin resistance.
• Crucially, unlike calcineurin inhibitors, mTOR inhibitors are not nephrotoxic.
• Metabolized by CYP3A4, creating a high potential for drug-drug interactions.